No stone left unturned: Challenges encountered during recruitment of women with advanced ovarian cancer for a phase I study

被引:5
作者
Albrecht, Tara A. [1 ]
Taylor, Ann Gill [1 ]
机构
[1] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA
关键词
Clinical trial research; Cancer; Recruitment; Research methodology; CLINICAL-TRIAL; MEDICINE USE; COMPLEMENTARY; ONCOLOGY; BARRIERS; MASSAGE; THERAPY;
D O I
10.1016/j.apnr.2013.05.003
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The recruitment and accrual of participants for cancer clinical trial research is often challenging. Chronic low accrual rates negatively influence the findings and generalizability that can be drawn from the available pool of research. There is a need for further evidence regarding both unsuccessful and successful approaches and useful strategies that investigators have used to counter common recruitment challenges. During recruitment for an intervention study examining the safety, efficacy, and feasibility of a potentially novel supportive therapy, a variety of steps were taken to avoid and subsequently overcome potential and real recruitment challenges the investigators faced. In this article the authors provide an overview of common recruitment challenges as well as the actual challenges encountered, procedures and strategies implemented to counter these challenges, while investigating the combined intervention of flaxseed oil, fasting, caffeine, and exercise in women with recurrent or multi-drug resistant stage HI or IV ovarian cancer. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:245 / 250
页数:6
相关论文
共 50 条
  • [1] An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer A Feasibility Study
    Mizrahi, David
    Broderick, Carolyn
    Friedlander, Michael
    Ryan, Mary
    Harrison, Michelle
    Pumpa, Kate
    Naumann, Fiona
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (06) : 985 - 992
  • [2] The perils of a vanishing cohort: a study of social comparisons by women with advanced ovarian cancer
    Morrell, Bronwen
    Jordens, Christopher F. C.
    Kerridge, Ian H.
    Harnett, Paul
    Hobbs, Kim
    Mason, Catherine
    PSYCHO-ONCOLOGY, 2012, 21 (04) : 382 - 391
  • [3] A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer
    Laber, Damian A.
    Khan, M. Iltaf
    Kloecker, Goetz H.
    Schonard, Cassandra
    Taft, Beverly S.
    Salvador, Carolina
    CANCER BIOLOGY & THERAPY, 2007, 6 (06) : 840 - 845
  • [4] Experiences and health care preferences of women with ovarian cancer during the diagnosis phase
    Jelicic, Lebecca
    Brooker, Joanne
    Shand, Lyndel
    Knight, Tess
    Ricciardelli, Lina
    Denham, Geoff
    Burney, Sue
    PSYCHO-ONCOLOGY, 2019, 28 (02) : 379 - 385
  • [5] Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
    Broekman, K. Esther
    Hof, Marieke A. J.
    Touw, Daan J.
    Gietema, Jourik A.
    Nijman, Hans W.
    Lefrandt, Joop D.
    Reyners, An K. L.
    Jalving, Mathilde
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1454 - 1462
  • [6] Recruitment challenges in clinical research: Survey of potential participants in a diagnostic study of ovarian cancer
    Sun, Zhuoyu
    Gilbert, Lucy
    Ciampi, Antonio
    Basso, Olga
    GYNECOLOGIC ONCOLOGY, 2017, 146 (03) : 470 - 476
  • [7] Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study
    Poort, Hanneke
    Fenton, Anny T. H. R.
    Thompson, Embree
    Dinardo, Margaret M.
    Liu, Joyce F.
    Arch, Joanna J.
    Wright, Alexi A.
    GYNECOLOGIC ONCOLOGY, 2021, 160 (01) : 227 - 233
  • [8] Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer
    Chambers, Laura M.
    Kuznicki, Michelle
    Yao, Meng
    Chichura, Anna
    Gruner, Morgan
    Reizes, Ofer
    Debernardo, Robert
    Rose, Peter G.
    Michener, Chad
    Vargas, Roberto
    GYNECOLOGIC ONCOLOGY, 2020, 159 (03) : 699 - 705
  • [9] Phase I/II study of docetaxel and S-I in patients with advanced gastric cancer
    Yamaguchi, K.
    Shimamura, T.
    Hyodo, I.
    Koizumi, W.
    Doi, T.
    Narahara, H.
    Komatsu, Y.
    Kato, T.
    Saitoh, S.
    Akiya, T.
    Munakata, M.
    Miyata, Y.
    Maeda, Y.
    Takiuchi, H.
    Nakano, S.
    Esaki, T.
    Kinjo, F.
    Sakata, Y.
    BRITISH JOURNAL OF CANCER, 2006, 94 (12) : 1803 - 1808
  • [10] Phase I study of green tea extract in patients with advanced lung cancer
    Laurie, SA
    Miller, VA
    Grant, SC
    Kris, MG
    Ng, KK
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (01) : 33 - 38